A new standard of care for patients with high-risk rhabdomyosarcoma? - Authors' reply

Lancet Oncol. 2020 Jan;21(1):e3. doi: 10.1016/S1470-2045(19)30812-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cyclophosphamide
  • Humans
  • Maintenance Chemotherapy*
  • Rhabdomyosarcoma*
  • Standard of Care
  • Vinorelbine

Substances

  • Cyclophosphamide
  • Vinorelbine